Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1480 · 1 trial · 1 indication
Progression-Free Survival (PFS) is defined as the time from randomization to the first occurrence of radiographic progression as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by Blinded Independent Central Review (BICR) or death from any cause, whichever occurs first.
Overall Survival (OS) is defined as the time from randomization to the event of death from any cause.
| Arm | Type | Description |
|---|---|---|
| ABBV-1480 + chemotherapy | EXPERIMENTAL | Participants will receive ABBV-1480 + chemotherapy (carboplatin and paclitaxel/nab-paclitaxel) |
| Pembrolizumab + chemotherapy | EXPERIMENTAL | Participants will receive Pembrolizumab + chemotherapy(carboplatin and paclitaxel/nab-paclitaxel) |
| Name | Type | Description |
|---|---|---|
| ABBV-1480 | DRUG | Intravenous (IV) |
| Pembrolizumab | DRUG | Intravenous (IV) |
| Carboplatin | DRUG | Intravenous (IV) |
| Paclitaxel | DRUG | Intravenous (IV) |
| Nab- Paclitaxel | DRUG | Intravenous (IV) |
Inclusion Criteria: * Adult subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or IV sqNSCLC that is not amenable to curative treatment * At least one lesion with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determin...
Top 20 of 84 competitors
ABBV-1480 is an investigational small molecule being developed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult participants. It is administered intravenously in combination with chemotherapy and is being compared against pembrolizumab combined with chemotherapy in a Phase 3 clinical trial.
ABBV-1480 is being developed by AbbVie Inc., a biopharmaceutical company publicly traded under the ticker symbol ABBV. The company is conducting a Phase 3 clinical trial to evaluate the drug in combination with chemotherapy for the first-line treatment of non-small cell lung cancer.
ABBV-1480 is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is designed to assess its efficacy and safety in adult patients with locally advanced or metastatic non-small cell lung cancer.
ABBV-1480 is being studied in a single Phase 3 clinical trial registered as NCT07756645. This randomized, controlled study compares intravenous ABBV-1480 combined with chemotherapy versus pembrolizumab combined with chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer in adults. The trial is not yet recruiting and plans to enroll 940 participants.
ABBV-1480 is administered intravenously in the ongoing Phase 3 clinical trial. The study combines ABBV-1480 with chemotherapy and compares this regimen to pembrolizumab plus chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in adult participants aged 18 years and older.